The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Ultomiris (ravulizumab) to reduce protein in the urine of adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of…

The approved, monthly therapy Voyxact (sibeprenlimab-szsi) can prevent kidney function worsening and kidney failure in adults with immunoglobulin A nephropathy (IgAN), according to final two-year results from a global, late-stage clinical trial. “VOYXACT…

I’ve always been aware of factors beyond my control; I just never considered that something outside my control might actually seriously affect me. Mysterious illnesses with complicated names have always existed, but they were something…